Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 12/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.38 |
| ▸ | CCR6 | P51684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310052 | 0.92 | CXCR1 (0.51) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18310049 | 0.88 | CXCR1 (0.53) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18314633 | 0.83 | CXCR1 (0.62) | CXCR1CXCR2ALDH1A1MEN1KMT2A | |
| SCHEMBL14904743 | 0.83 | CXCR1 (0.62) | CXCR1CXCR2ALDH1A1MEN1KMT2A | |
| SCHEMBL18310056 | 0.82 | CXCR1 (0.51) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18314666 | 0.77 | ALDH1A1 (0.51) | CXCR1CXCR2ALDH1A1MEN1KMT2A | |
| SCHEMBL14904742 | 0.76 | ALDH1A1 (0.49) | CXCR1CXCR2ALDH1A1MEN1KMT2A | |
| SCHEMBL14904768 | 0.74 | CXCR1 (0.60) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18314629 | 0.74 | CXCR1 (0.60) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL14904738 | 0.73 | MAPT (0.56) | CXCR1CXCR2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | disclosed |
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCR1, CCL11 | CXCR1 10/4885CXCR2 9/4885ALDH1A1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.